title: A case of recalcitrant epidermolysis bullosa acquisita responsive to rituximab therapy.
abstract: Epidermolysis bullosa acquisita (EBA) is an autoimmune blistering disorder that occurs infrequently in children. Although typically associated with a good prognosis in children, there are rare cases that are refractory to treatment with conventional immunosuppressive therapy. Rituximab, an anti-CD20 monoclonal antibody, has been reported to be effective in the adult form of EBA. We report a case of a child with severe and recalcitrant EBA exhibiting a sustained response to treatment with rituximab.
authors.affiliation: Harvard Medical School, Children's Hospital Boston, Boston, Massachusetts.
authors.forename: Sophia K
authors.initials: SK
authors.lastname: McKinley
authors.forename: Jennifer T
authors.initials: JT
authors.lastname: Huang
authors.forename: Jennifer
authors.initials: J
authors.lastname: Tan
authors.forename: Daniela
authors.initials: D
authors.lastname: Kroshinsky
authors.forename: Stephen
authors.initials: S
authors.lastname: Gellis
mesh_terms: D000293:Adolescent; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D016107:Epidermolysis Bullosa Acquisita / Q000188:drug therapy*; D006801:Humans; D008297:Male; D000069283:Rituximab
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab